Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B

Hepatology Research

Volumn 40, Issue 3, 2010, Pages 269-277

  Tangkijvanich, Pisit ^a   Komolmit, Piyawat ^a   Mahachai, Varocha ^a   Sa nguanmoo, Pattaratida ^a   Theamboonlers, Apiradee ^a   Poovorawan, Yong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Covalently closed circular DNA; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus DNA; Pegylated interferon; Quantification; Virological response

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; DNA DETERMINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; TREATMENT RESPONSE;

EID: 77953282645     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00592.x     Document Type: Article

References (34)

1. Ganem D, Prince AM. Hepatitis b virus infection - natural history and clinical consequences. N Engl J Med 2004, 350:1118-29.
2. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45:1056-75.
3. Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. Interferon therapy for chronic hepatitis B. Clin Liver Dis 2007, 11:viii-49.
4. Bowden S. Serological and molecular diagnosis. Semin Liver Dis 2006, 26:97-103.
5. Brunetto MR, Moriconi F, Bonino F. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2008, 49:1141-50.
6. Chan HL, Wong VW, Tse AM. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5:1462-8.
7. Fried MW, Piratvisuth T, Lau GK. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008, 47:428-34.
8. Moucari R, Mackiewicz V, Lada O. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2008, 49:1151-7.
9. Ozaras R, Tabak F, Tahan V. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 2008, 53:2995-8.
10. Knodell RG, Ishak KG, Black WC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-5.
11. Pawlotsky JM, Dusheiko G, Hatzakis A. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008, 134:405-15.
12. Deguchi M, Yamashita N, Kagita M. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004, 115:217-22.
13. Wiegand J, Wedemeyer H, Finger A. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008, 13:547-54.
14. Payungporn S, Tangkijvanich P, Jantaradsamee P, Theamboonlers A, Poovorawan Y. Simultaneous quantitation and genotyping of hepatitis B virus by real-time PCR and melting curve analysis. J Virol Methods 2004, 120:131-40.
15. He ML, Wu J, Chen Y, Lin MC, Lau GK, Kung HF. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun 2002, 295:1102-7.
16. Shadrina MI, Semenova EV, Slominsky PA. Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage. BMC Med Genet 2007, 8:6.
17. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-500.
18. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008, 28:1067-77.
19. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009, 16:265-71.
20. Janssen HL, van Zonneveld M, Senturk H. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-9.
21. Lau GK, Piratvisuth T, Luo KX. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-95.
22. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006, 44:694-702.
23. Werle-Lapostolle B, Bowden S, Locarnini S. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126:1750-8.
24. Wong DK, Yuen MF, Yuan H. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004, 40:727-37.
25. Sung JJ, Wong ML, Bowden S. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005, 128:1890-7.
26. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005, 42:302-8.
27. Wursthorn K, Lutgehetmann M, Dandri M. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-84.
28. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antiviral therapy 2007, 12:73-82.
29. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996, 91:2323-8.
30. Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000, 7:382-6.
31. Perrillo R, Mimms L, Schechtman K, Robbins D, Campbell C. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology 1993, 18:1306-12.
32. ter Borg MJ, van Zonneveld M, Zeuzem S. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006, 44:721-7.
33. Chan HL, Wong VW, Wong GL. DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008, 6:1022-6.
34. Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 2006, 44:S10-13.